BCL2L1 and colonic neoplasm: To confirm the BCLXL dependency in 5-FU-resistant HT-29 cells, we first treated parental and 5-FU-resistant colon cancer cells with the BCLXL-specific inhibitor WEHI-539 and assessed the effect of this inhibition on cell survival.